Kalaris Therapeutics, Inc. (KLRS) - Total Assets
Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) holds total assets worth $81.17 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Kalaris Therapeutics, Inc. for net asset value and shareholders' equity analysis.
Kalaris Therapeutics, Inc. - Total Assets Trend (2018–2024)
This chart illustrates how Kalaris Therapeutics, Inc.'s total assets have evolved over time, based on quarterly financial data.
Kalaris Therapeutics, Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Kalaris Therapeutics, Inc.'s total assets of $81.17 Million consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 99.8% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Kalaris Therapeutics, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KLRS company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kalaris Therapeutics, Inc.'s current assets represent 100.0% of total assets in 2024, an increase from 100.0% in 2018.
- Cash Position: Cash and equivalents constituted 99.8% of total assets in 2024, up from 98.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kalaris Therapeutics, Inc. Competitors by Total Assets
Key competitors of Kalaris Therapeutics, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Kalaris Therapeutics, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.89 | 0.16 | 29.39 |
| Quick Ratio | 12.89 | 0.16 | 29.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $72.12 Million | $-11.62 Million | $349.02 Million |
Kalaris Therapeutics, Inc. - Advanced Valuation Insights
This section examines the relationship between Kalaris Therapeutics, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.10 |
| Latest Market Cap to Assets Ratio | 0.86 |
| Asset Growth Rate (YoY) | 3456.7% |
| Total Assets | $118.55 Million |
| Market Capitalization | $102.12 Million USD |
Valuation Analysis
Near Book Valuation: The market values Kalaris Therapeutics, Inc.'s assets close to their book value (0.86x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Kalaris Therapeutics, Inc.'s assets grew by 3456.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Kalaris Therapeutics, Inc. (2018–2024)
The table below shows the annual total assets of Kalaris Therapeutics, Inc. from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $118.55 Million | +3456.74% |
| 2023-12-31 | $3.33 Million | -14.52% |
| 2022-12-31 | $3.90 Million | -98.64% |
| 2021-12-31 | $286.59 Million | -22.71% |
| 2020-12-31 | $370.82 Million | +165.97% |
| 2019-12-31 | $139.42 Million | +450.66% |
| 2018-12-31 | $25.32 Million | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.